Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page

Private Equity Accelerating Consolidation In The CDMO Market

Skip to the end of the Expertise Menu

Private Equity Accelerating Consolidation In The CDMO Market

The CDMO industry has benefitted from big pharma’s divestment of in-house development and manufacturing capabilities in this current economic cycle. The sector has grown at a consistent 7 percent compound annual growth rate (CAGR) for the better part of a decade, outpacing that of the greater pharmaceutical industry itself. The rise of competition from new CDMO players and consolidation within the pharmaceutical sponsor space, however, has led to a crowded market and, in many cases, a commoditized service base.

To compete in this environment, CDMOs have utilized various strategies to achieve economies of scale, diversify their service offerings, and vertically integrate to create a more marketable offering to the sponsor community.

To read the full article written by AJ Shekar and Bill Bolding, click here: Private Equity Accelerating Consolidation In The CDMO Market

About Outsourced Pharma

Outsourced Pharma provides comprehensive analysis of global outsourcing, the biotechnology and pharmaceutical industries, and their intersection with the overall life sciences and health care markets. We offer readers a deeper exploration and understanding of the relationships between service providers and their Bio and Pharma sponsors.  To learn more, visit https://www.outsourcedpharma.com/.